Title Originator Highest Dev Status
111In-capromab pendetide Cytogen Corp Launched
111In-imciromab pentetate Janssen Biotech Inc Launched
131I-chTNT-1/B Peregrine Pharmaceuticals Inc Launched
131I-metuximab Fourth Military Medical University PLA Launched brentuximab vedotin Seattle Genetics Inc Launched gemtuzumab Wyeth Research Launched ibritumomab tiuxetan IDEC Pharmaceuticals Corp Launched trastuzumab emtansine Genentech Inc Launched
ATL-101, ATLAB Cornell University Phase 3 Clinical inotuzumab ozogamicin Wyeth Research Phase 3 Clinical oportuzumab monatox (intratumoral, head and neck cancer), Viventia University of Zurich Phase 3 Clinical RIGS CC49Navidea Biopharmaceuticals Inc Phase 3 Clinical ABT-414Abbott Laboratories Phase 2 Clinical CDX-1401Celldex Therapeutics Inc (pre-merger)Phase 2 Clinical glembatumumab vedotin CuraGen Corp Phase 2 Clinical LMB-2National Cancer Institute Phase 2 Clinical lorvotuzumab mertansine ImmunoGen Inc Phase 2 Clinical moxetumomab pasudotox National Cancer Institute Phase 2 Clinical oportuzumab monatox (intravesicular, bladder cancer), Viventia University of Zurich Phase 2 Clinical PSMA-ADC Cytogen Corp Phase 2 Clinical RG-7593Genentech Inc Phase 2 Clinical RG-7596Genentech Inc Phase 2 Clinical SAR-3419ImmunoGen Inc Phase 2 Clinical 212-Pb-TCMC-trastuzumab National Cancer Institute Phase 1 Clinical Actimab-A PDL BioPharma Inc Phase 1 Clinical AGS-16M8F Agensys Inc Phase 1 Clinical anti-CD3/anti-CD20 bispecific antibody-armed activated T-cells (non-
Hodgkin's lymphoma), Wayne State University/Barbara Ann Karmanos
Cancer Institute Barbara Ann Karmanos Cancer Institute Phase 1 Clinical ASG-5ME Agensys Inc Phase 1 Clinical BAY-79-4620MorphoSys AG Phase 1 Clinical citatuzumab bogatox Viventia Biotech Inc Phase 1 Clinical doxorubicin-loaded anti-EGFR immunoliposomes (solid tumors), University
Hospital Basel University Hospital of Basel Phase 1 Clinical HuM195/rGel (intravenous infusion, AML/CML/meylodisplastic syndrome),
Targa Therapeutics Memorial Sloan-Kettering Cancer Center Phase 1 Clinical IMGN-529ImmunoGen Inc Phase 1 Clinical IMGN-853ImmunoGen Inc Phase 1 Clinical IMMU-132Immunomedics Inc Phase 1 Clinical labetuzumab-SN-38Immunomedics Inc Phase 1 Clinical
NHS-IL-12National Cancer Institute Phase 1 Clinical RG-7450Genentech Inc Phase 1 Clinical RG-7458Genentech Inc Phase 1 Clinical RG-7598Genentech Inc Phase 1 Clinical RG-7599Genentech Inc Phase 1 Clinical RG-7600Genentech Inc Phase 1 Clinical RG-7636Genentech Inc Phase 1 Clinical SAR-566658ImmunoGen Inc Phase 1 Clinical T-Guard University Medical Center St Radboud Phase 1 Clinical vorsetuzumab mafodotin Seattle Genetics Inc Phase 1 Clinical 131I-catuximab (colorectal cancer), Pacific Meinuoke Fourth Military Medical University PLA Discovery
177Lu-tetraxetan-tetulomab (non-Hodgkin's lymphoma), Nordic Nanovector Nordic Nanovector AS Discovery
227Th-epratuzumab (hematological cancer), Algeta Algeta ASA Discovery
227Th-rituximab (cancer), Algeta Algeta ASA Discovery
227Th-trastuzumab (cancer), Algeta Algeta ASA Discovery
4s3-0014s3 Bioscience Inc Discovery
4s3-0024s3 Bioscience Inc Discovery
64Cu-NOTA-ALT-836Altor BioScience Corp Discovery
AA-A225Actinium Pharmaceuticals Inc Discovery AbGn-107AbGenomics Corp Discovery Actimab-B Fred Hutchinson Cancer Research Center Discovery Actimab-C Actinium Pharmaceuticals Inc Discovery Actimab-P Actinium Pharmaceuticals Inc Discovery adalimumab + anti-Ang2 Zybody (rheumatoid arthritis/inflammatory bowel
disease), Zyngenia Zyngenia Inc Discovery
AGS-15E ADC Agensys Inc Discovery
AGT-160ArmaGen Technologies Inc Discovery
AGT-185ArmaGen Technologies Inc Discovery
AGT-190ArmaGen Technologies Inc Discovery amanitin-trastuzumab conjugate (cancer), Heidelberg Pharma Heidelberg Pharma Holding Ltd Discovery
anti-CD133-immunotoxin conjugates (photochemical internalization, cancer),
PCI Biotech PCI Biotech Holding ASA Discovery
anti-ET8R-MC-vc-PAB-MMAE Genentech Inc Discovery
anti-NaPi3b antibody-drug conjugate (cancer), Genentech/Roche Genentech Inc Discovery antibody drug conjugates (cancer), Sanofi Sanofi Discovery antibody-drug conjugates (cancer), ADC Therapeutics ADC Therapeutics Sarl Discovery antibody-drug conjugates (cancer), Seattle Genetics/Oxford BioTherapeutics Seattle Genetics Inc Discovery antibody-drug conjugates (TAP, cancer), Lilly Eli Lilly & Co Discovery antibody-IFN lambda conjugates (cancer), Immunomedics Immunomedics Inc Discovery anticancer therapy (TAP technology), Amgen Amgen Inc Discovery
APH-0912Aphios Corp Discovery Aurixin BioIntegrator Discovery
AZ-05Allozyne Inc Discovery BIOO-1BIOO Therapeutics Discovery BIOO-2BIOO Therapeutics Discovery BIOO-3BIOO Therapeutics Discovery BIOO-4BIOO Therapeutics Discovery BIOO-5BIOO Therapeutics Discovery BIOO-6BIOO Therapeutics Discovery BIOO-7BIOO Therapeutics Discovery botulinum toxin B inhibitor (injectable, heteropolymer mAbs, botulism),
Immunome Immunome Inc Discovery BT-2111biOasis Technologies Inc Discovery C2-2b-2b Immunomedics Inc Discovery CDX-014CuraGen Corp Discovery chiHEA-125-Ama Heidelberg Pharma Holding Ltd Discovery CK-22-(20)-(20)Immunomedics Inc Discovery complement factor H-derived short consensus repeat-antibody constructs
(infection), LysoVac University of Innsbruck Discovery Cymac-001Cytoguide ApS Discovery CYP-Ab Cytune Pharma Discovery D2C7-based immunotoxins (glioma), Duke University Duke University Discovery EGFR modulators (antibody conjugates, PIT, cancer), Aspyrian Aspyrian Therapeutics Inc Discovery engineered cysteine drug conjugates mAbs (cancer), Seattle Genetics Seattle Genetics Inc Discovery epratuzumab-SN-38Immunomedics Inc Discovery ETBs (cancer), Molecular Templates/ Imclone Molecular Templates Inc Discovery Fluorescent-labeled bevacizumab (imaging, ocular disease), Mivenion mivenion Gmbh Discovery gemcitabine + paclitaxel (prodrug, nanomAb, cancer), Immune
Pharmaceuticals Immune Pharmaceuticals Corp Discovery Herceptin:Endostatin-P125A University of Miami Discovery hLL1-CL2A-SN-38Immunomedics Inc Discovery hPAM4-CL2A-SN-38Immunomedics Inc Discovery human monoclonal antibody-toxin conjugates (myocardial infarction), Celdara Celdara Medical LLC Discovery HuMax-TF-ADC Genmab A/S Discovery IFNalpha-fused mAbs (HBV infection), Roche Roche Holding AG Discovery IL-13 receptor alpha 2 inhibitors (iv, cancer), Pfizer Pfizer Inc Discovery IMGN-289ImmunoGen Inc Discovery intracellular antibodies (Intraphilin, inflammatory diseases/infectious
diseases/ophthalmic diseases), Permeon Biologics Permeon Biologics Inc Discovery mapp-66Mapp Biopharmaceutical Inc Discovery MB-2003Mapp Biopharmaceutical Inc Discovery monoclonal antibody-drug conjugates, Chirogenix/ImmunoGen/Celltrion Chirogenix Co Ltd Discovery MP-Ter-ADC MediaPharma Srl Discovery N01-OX2Intellect Neurosciences Inc Discovery
PC-91ProCell Therapeutics Inc Discovery ProstaLite PhotoBiotics Ltd Discovery recombinant mAb-biocide fusion proteins (oral/Directed Biocide,
cryptosporidium infection), ioGenetics ioGenetics Inc Discovery SGN-CD33A Seattle Genetics Inc Discovery SGN-LIV1A Seattle Genetics Inc Discovery SL-101Stemline Therapeutics Inc Discovery SYD-983Synthon Biopharmaceuticals Discovery T01-OX2Intellect Neurosciences Inc Discovery TBL-0306L Transgene Biotek Ltd Discovery TBL-0306M Transgene Biotek Ltd Discovery TBL-0805E Transgene Biotek Ltd Discovery thio-trastuzumab-mpeo-DM1Genentech Inc Discovery trastuzumab-PNU-159682 antibody-drug conjugate (cancer), Genentech Genentech Inc Discovery veltuzumab-IFN alpha 2b conjugate (cancer), IBC/Immunomedics IBC Pharmaceuticals Inc Discovery BIIB-015Biogen Inc Suspended Pretarget technology (gastrointestinal adenocarcinoma), NeoRx Poniard Pharmaceuticals Inc Suspended
125I-AnnA1 IgG Sidney Kimmel Cancer Center No Development Reported
131I-CC49-SCA Enzon Labs Inc No Development Reported
177Lu-capromab pendetide Cytogen Corp No Development Reported
90Y-capromab pendetide Cytogen Corp No Development Reported
99mTC-BERH2Medac GmbH No Development Reported
anti-CD133-vcMMAF Seattle Genetics Inc No Development Reported
anti-CD22 antibody drug-conjugates, Medarex/BMS Medarex Inc No Development Reported
anti-PSMA antibody-drug conjugates (cancer), Medarex Medarex Inc No Development Reported
antibody-drug conjugates (solid tumors), Daiichi Sankyo Seattle Genetics Inc No Development Reported
AVE-9633ImmunoGen Inc No Development Reported
bectumomab Immunomedics Inc No Development Reported
CA125/MUC16-targeting antibody-drug conjugate (ovarian cancer),
Genentech Genentech Inc No Development Reported
cathepsin B-sensitive prodrugs, BMS Bristol-Myers Squibb Pharmaceutical Research
Institute
No Development
Reported
CC49 humanized radioimmunoconjugates, National Cancer Institute,
University of Alabama at Birmingham National Cancer Institute No Development Reported
CD4-BFFI Roche Holding AG No Development Reported
CHB-111ViRexx Medical Corp No Development Reported
CHT-25University College London No Development Reported
CMD-193Wyeth No Development Reported
CNTO-95 immunoconjugates (cancer), Centocor Janssen Biotech Inc No Development Reported
conjugated PEI/anti-CD133 mAb plasmid-based gene therapy (brain tumor),
Discovery genomics Discovery Genomics Inc No Development Reported
cT84.66City of Hope No Development Reported
delta 9-cadherin targeting antibody (gastric cancer), Actinium Helmholtz Zentrum München No Development Reported
diphtheria toxin, RCT Research Corporation Technologies No Development Reported
doxorubicin-C225 conjugate (STEALTH), SEQUUS SEQUUS Pharmaceuticals Inc No Development Reported
DTPA-BrE-3University of Colorado System No Development Reported
DXL-625InNexus Biotechnology Inc No Development Reported
G3.519-PAP-S Tanox Inc No Development Reported
huHMFG1-caspase Antisoma plc No Development Reported
IMGN-007ImmunoGen Inc No Development Reported
IMGN-009ImmunoGen Inc No Development Reported
immunoconjugate (cancer MN), Bayer Bayer AG No Development Reported
ImmuRAID-AFP-99mTc, Immunomedics Immunomedics Inc No Development Reported
IMTOX 22-97A University of Texas Southwestern Medical
Center
No Development
Reported
KSB-201KS Biomedix Holdings plc No Development Reported
LA22-radioimmunoconjugates (cancer), Welson/Peking University Welson Pharmaceuticals Inc No Development Reported
labetuzumab Immunomedics Inc No Development Reported
LMB-1, NIH National Institutes of Health No Development Reported
Lu-177-trastuzumab Tarbiat Modares University No Development Reported
LymphoScan Immunomedics Inc No Development Reported
MDX-11Medarex Inc No Development Reported
MDX-1203Medarex Inc No Development Reported
MDX-1206Medarex Inc No Development Reported
monoclonal-porphyrins, Quadra Logic QLT Inc No Development Reported
monoclonals, Quest Quest Biotechnology Inc No Development Reported
Nogo receptor modulators, Biogen Idec Yale University No Development Reported
ONS-1210Oncobiologics Inc No Development Reported
OP-06 program (cancer), Onco-Pharmakon Onco-Pharmakon Inc No Development Reported
paclitaxel analogs and immunoconjugates (cancer), Bioxel Bioxel Pharma Inc No Development Reported
PE38-conjugated anti-CD30 immunotoxin, NCI National Cancer Institute No Development Reported
prostate-specific MAb, NIH National Institutes of Health No Development Reported
R-1549The UK Imperial Cancer Research Fund No Development Reported
radiolabeled Tx3.833Beth Israel Deaconess Medical Center No Development Reported
scu-PA-59D8Bristol-Myers Squibb Co No Development Reported
SGN-17/19Seattle Genetics Inc No Development Reported
taxane-monoclonal antibody conjugates, ImClone ImClone Systems Inc No Development Reported
transcobalamin (vitamin B12) receptor-targeting mAbTCR23-saporin
conjugate (cancer), Kyto Kyto Biopharma Inc No Development Reported
trastuzumab-autophilic peptide conjugate (breast cancer), InNexus
Biotechnology InNexus Biotechnology Inc No Development Reported
trastuzumab-MC-vc-PAB-MMAF Genentech Inc No Development Reported
TRP-targeted antibody conjugate (Yttrium 90/MX-DTPA), Somanta
Pharmaceuticals Immunodex Inc No Development Reported
tucotuzumab celmoleukin EMD Lexigen Research Center Corp No Development Reported
VB4-011Viventia Biotech Inc No Development Reported
VB6-011Viventia Biotech Inc No Development Reported
VB6-050Viventia Biotech Inc No Development Reported
XomaZyme-791XOMA Corp No Development Reported
nofetumomab Poniard Pharmaceuticals Inc Withdrawn 131I-81C6Duke University Discontinued 131I-ImmuRAIT-HCG, Immunomedics Immunomedics Inc Discontinued B-B4-DC1ImmunoGen Inc Discontinued CC49 radioimmunoconjugates, University of Alabama at Birmingham University of Alabama at Birmingham Discontinued CD5 monoclonals/RIPs, Italfarmaco Italfarmaco SpA Discontinued CVX-045CovX Pharmaceuticals Inc Discontinued CVX-060CovX Pharmaceuticals Inc Discontinued CVX-241CovX Pharmaceuticals Inc Discontinued CVX-343CovX Pharmaceuticals Inc Discontinued doxorubicin-BR96 conjugate, BMS Bristol-Myers Squibb Co Discontinued doxorubicin-CEA conjugate, Immunomedics Immunomedics Inc Discontinued doxorubicin-LL2 conjugate, Immunomedics Immunomedics Inc Discontinued FAP5-DM1Boehringer Ingelheim Corp Discontinued FGFR4-CovX-Body CovX Pharmaceuticals Inc Discontinued HuM-195-Bi-213PDL BioPharma Inc Discontinued human placental growth factor 1-CVX-2000 monoclonal antibody conjugated
therapeutic (CovX-body, cancer), CovX CovX Pharmaceuticals Inc Discontinued huN901-CC-1065ImmunoGen Inc Discontinued huN901-DC1ImmunoGen Inc Discontinued ImmuRAID-HCG-99mTc, Immunomedics Immunomedics Inc Discontinued ImmuRAIT-CEA-rhenium-188, Immunomedics Immunomedics Inc Discontinued MDX-214Medarex Inc Discontinued MEDI-547MedImmune LLC Discontinued MLN-2704Cornell University Discontinued
Oncolym Peregrine Pharmaceuticals Inc Discontinued Oncolysin B Dana-Farber Cancer Institute Inc Discontinued Oncolysin CD6Dana-Farber Cancer Institute Inc Discontinued Oncolysin M Dana-Farber Cancer Institute Inc Discontinued Oncolysin S Dana-Farber Cancer Institute Inc Discontinued Oncopurge Poniard Pharmaceuticals Inc Discontinued rhenium-188-LL2, Immunomedics Immunomedics Inc Discontinued SMART ABL-364Novartis AG Discontinued targeted ranpirnase conjugates (cancer), Alfacell Tamir Biotechnology Inc Discontinued